| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Frank E Thomas is Director at SPRO, with reported holdings spanning 2 companies. Frank E Thomas's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $106K at current prices.
Frank E Thomas's largest disclosed position is in SPRO as Director, worth about $88K.
Frank E Thomas has 26 Form 4 filings on record from July 2015 to June 2026, across 2 companies: Director at Spero Therapeutics (SPRO), 2018–2026; Director at Larimar Therapeutics (LRMR), 2015–2026.
The 27 reported transactions were 20 option or other derivative awards, 5 stock awards and 2 open-market purchases.
Counted by filing, the open-market trades come to 2 purchases worth about $47K and no sales.
The largest open-market purchase was 5,000 shares of LRMR at an average $5.00 on February 27, 2026, about $25K.